Ibrutinib in combination with venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||27/07/2022|
|Rapid review completed||02/09/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of ibrutinib in combination with venetoclax compared with the current standard of care.|